The analysis revealed that ARID1B hypermethylation could serve as an early diagnostic biomarker for COAD treatment, and the difference in immune cell infiltration was found to be related to the ARID1B expression of the COAD tumour. This evidence concerns the gene ARID1B and colon adenocarcinoma.